Rock Springs Capital, based in Maryland, is an equity hedge fund manager specializing in discretionary investment advice within the health sciences sector, focusing on biotechnology and pharmaceuticals. Founded in October 2013 by Kris Jenner, a former equity portfolio manager at T. Rowe Price, the firm targets strategic investments in these industries.
Kris Jenner is a founding partner of Rock Springs Capital, an investment firm focused on global healthcare investing. Before Rock Springs, Kris spent over 15 years at T. Rowe Price, specializing in the pharmaceutical and biotechnology industries. From 2000 to February 2013, Kris managed the T. Rowe Price Health Sciences Fund, a top-performing multi-billion dollar strategy. Kris holds an M.D. from The Johns Hopkins School of Medicine, a D. Phil. from Oxford University in molecular biology as a Marshall Scholar, and a B.S. in chemistry, summa cum laude, from the University of Illinois.
Gordon Magraf Bussard co-founded Rock Springs Capital Management LP in 2013 and served as a Limited Partner & Member. Before this, he was Vice President & Analyst at T. Rowe Price Associates, Inc. from 2005 to 2013. Dr. Bussard earned his undergraduate degree from Williams College in 1994, an MBA from the University of Virginia Darden School of Business in 2002, and a doctorate from The University of Virginia School of Medicine in 1998. He is also the founder of Rivanna Pharmaceuticals, Inc.
Graham McPhail currently serves as a Securities Analyst at Rock Springs Capital, leveraging experience gained from previous roles at T. Rowe Price, The Boston Company, Evergreen Investments, and Cardinal Capital Management LLC. He earned his MBA from the University of Virginia Darden School of Business from 2002 to 2004.
Rock Springs Capital Management manages discretionary assets totaling $5,768,717,819 for six clients, as reported in their Form ADV on March 2024. Their Q1 2024 13F filing disclosed holdings of $3,938,846,355 in managed 13F securities, with a top 10 holdings concentration of 32.83%. The firm's largest holding is Blueprint Medicines Corp, with 2,498,448 shares held.